Increased migration inhibition factor production by leukocytes of patients with herpes zoster given the leukocyte ultrafiltrate.
Using the direct leukocyte migration inhibition assay, the cell-mediated immune response was followed in together 47 patients suffering from herpes zoster. Of these, 19 persons were treated with partially purified and concentrated lysed leukocyte ultrafiltrate. Enhancement and/or earlier production of the leukocyte migration inhibition factor--in the presence of varicella-zoster virus antigen--was observed by leukocytes from patients given the ultrafiltrate on days 2-3 since the onset of the vesicular stage of the disease. Highly significant (alpha = 1%, P less than 0.01) differences in the migration inhibition values were observed between non-treated patients and patients given one dose of the ultrafiltrate during the days 3-12 after appearance of the first herpes zoster vesicles; on days 13-30 these values were not significant.
Lackovicová
M
M
Institute of Virology, Slovak Academy of Science, Bratislava, Czechoslovakia.
Zachar
V
V
Necas
S
S
Mayer
V
V
D000293:Adolescent; D000328:Adult; D000368:Aged; D001685:Biological Factors / Q000302:isolation & purification / Q000627:therapeutic use*; D002648:Child; D006562:Herpes Zoster / Q000276:immunology / Q000628:therapy*; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007961:Leukocyte Migration-Inhibitory Factors / Q000096:biosynthesis*; D007962:Leukocytes / Q000276:immunology*; D008222:Lymphokines / Q000096:biosynthesis*; D008875:Middle Aged; D014462:Ultrafiltration
D001685:Biological Factors; D007961:Leukocyte Migration-Inhibitory Factors; D008222:Lymphokines